IL6 and rheumatoid arthritis: Among all these candidate target cytokines, IL-6 seems to be one of the best choices, particularly for COVID-19 patients with RA: from the aspects of either availability of the products or the current evidences supporting the benefits in treating both of the diseases [4, 18–21].